Cytokinetics (CYTK) Common Equity (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Common Equity of -$826.6 million for Q1 2026, down 210.26% year-over-year from $749.7 million in Q1 2025, and down 25.31% quarter-over-quarter from -$659.6 million in Q4 2025.
Cytokinetics (CYTK) Common Equity (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Common Equity for 17 consecutive years, with -$826.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 210.26% year-over-year to -$826.6 million; the TTM figure through Mar 2026 stood at -$826.6 million (down 210.26% YoY), while the FY2025 annual figure was -$659.6 million, down 387.27% from the prior year.
- Common Equity eased to -$826.6 million in Q1 2026 per CYTK's latest filing, from -$659.6 million in the prior quarter.
- Across five years, Common Equity topped out at $116.3 million in Q1 2022 and bottomed at -$826.6 million in Q1 2026.
- Historically, Common Equity has averaged -$256.6 million across 5 years, with a median of -$266.4 million in 2025.
- Annual changes were most pronounced in 2022 — Common Equity soared 575.69% — and 2025, when it plunged 3646.12%.
- Cytokinetics' Common Equity stood at -$107.9 million in 2022, then plunged by 258.04% to -$386.3 million in 2023, then soared by 64.96% to -$135.4 million in 2024, then sank by 387.27% to -$659.6 million in 2025, then declined by 25.31% to -$826.6 million in 2026.
- Business Quant data shows CYTK's Common Equity at -$826.6 million in Q1 2026, -$659.6 million in Q4 2025, and -$521.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -173.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -173.49 Mn |
| Mar 31, 2026 | -826.57 Mn |
| Dec 31, 2025 | -659.63 Mn |
| Sep 30, 2025 | -521.12 Mn |
| Jun 30, 2025 | -368.72 Mn |
| Mar 31, 2025 | -266.41 Mn |
| Dec 31, 2024 | -135.37 Mn |
| Sep 30, 2024 | -13.91 Mn |
| Jun 30, 2024 | 108.55 Mn |
| Mar 31, 2024 | -396.16 Mn |
| Dec 31, 2023 | -386.32 Mn |
| Sep 30, 2023 | -438.80 Mn |
| Jun 30, 2023 | -333.12 Mn |
| Mar 31, 2023 | -229.02 Mn |
| Dec 31, 2022 | -107.90 Mn |
| Sep 30, 2022 | -15.98 Mn |
| Jun 30, 2022 | 111.41 Mn |
| Mar 31, 2022 | 116.26 Mn |
| Dec 31, 2021 | 243.86 Mn |
| Sep 30, 2021 | 249.02 Mn |